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Histamine release and adverse pseudoaller~iclaller~~c re- 
actions during the perioperatiue period occur frequently. The 
incidence of such reactions is 20%~30% for all <grades of 
severity, 1 o/,--5% for systemic reactions, and 0.1 S-0.5% 
,for life-threatening reactions. They can be elicited by all 
commonly used anesthetic agents and by surgical interven- 
tions. Both the incidence and severity can be reduced by the 
use of combined prophylaxis with H,- -I- H,-receptor an- 
tagonists. The authors recommend that this prophylaxis be 
given to the,following groups of patients: those with a history 
of adverse reactions or history of allergy, patients undergoing 
surgeq with a high risk of histamine release, elderly patients, 
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and those with poor physical statw due to underlying systemic 
diseases. These indications have been developed by heuristic 
m,edical decision-making, including a derision tree. 
Keywords: Ih-ugs, adverse reactions; risk factors; 
histamine; histamine antagonists: allergy; anesthesia. 
Introduction 
Histamine release and undesired histamine release 
reactions during anesthesia and surgery have been 
the subject of’ extensive and persistent research in 
~lnesthesiology,‘~“’ pharmacology,“- I’ and clinical 
iliimunology’~~‘H over the last 20 years. This activity 
stands in marked contrast to the regrettable f‘act that 
the wealth of’ consistent data in this field’-lx is not 
widely appreciated by anesthesiologists in daily prac- 
tice. Unwanted histamine release reactions appear 
clinically as pseudoallergic and allergic reactionsI but 
also as “atypical” disease entities such as significant 
arrhythmias, hypertension, myocardial inf‘arction,‘!‘~” 
vomiting and diarrhea,“’ and thrombosis.” The re- 
actions are caused by the administration of’ several 
drugs during anesthesia” and by various physical ac- 
tions, P.R., intubation2’ and measures of surgical in- 
tervention.“’ ‘They occur more frequently than is 
generally supposed. Using data obtained from pro- 
spective clinical trials, the overall incidence of reac- 
tions is about 20%-30%, including increased gastric 
acid secretion.‘,‘” Systemic reactions occur in 1 S--5%, 
and life-threatening reactions occur in 0.1 S--0.5% of 
patlents.zl 
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Why don’t many countries accept the fact that 
antihistamines should be given to some groups of 
surgical patients? A language barrier could be at 
fault. ‘l-he first report associating increased plasma 
histamine concentrations and clinical symptoms after 
administration of the hypnotics thiopental sodium and 
propanidid (Epontol@) in routine anesthesia was pub- 
lished in 1970.2” Based on data from a randomized 
clinical trial, the same group first demonstrated that 
adverse pseudoallergic reactions could be prevented 
completely by administering histamine H,- + H,- 
receptor antagonists.“’ However, since that trial more 
than 10 years ago,“’ this subject has been discussed 
without definitive resolution, a situation that now has 
led to an international niulticenter trial.“‘~“’ 
In this review, the incidence of adverse pseudoal- 
lergic and allergic reactions seen during anesthesia 
and surgery is addressed, as are the pharmacology of’ 
H ,- + H,-antihistamirles and the current state of’ the 
art regarding the effectiveness of a combined pro- 
phylaxis with H ,- + I-l,-receptor antagonists. Finally, 
a decision tree hr- a problem solving strategy leading 
to recornIiierldatiotls for the use of H ,- + H,-blockade 
as a systematic approach to prevent or reduce the 
severity of such reactions is presented. 
Histamine Release Reactions, Allergic 
and Pseudoallergic Reactions: 
Classification by Pathomechanisms 
Histamine release reactions in anesthesia and sur- 
gery,YH also those reactions to intubation and surgical 
trauma if the extent of histamine release elicited causes 
clinical symptoms,“’ ’ ‘Ire a subset of adverse I-espo1w3 
resembling hypersensitivitv reactions. ‘I‘he latter arc 
classified either as allergic (involving immunr proc- 
esses) or pseudoallergic (in which the immune system 
is not involved or its involvement has not been den- 
onstrated) (Tuble I).‘!’ Both allergic and pseudoallergic 
reactions can present with the same clinical symptoms; 
however, no previous contact is required in pseu- 
doallergic reactions. More than one mechanism may 
be involved in reactions to a single drug. Thus, in 
reactions involving thiopental, 3% are allergic type 
I, 10% are allergic reactions involving complement, 
4% are pseudoallergic reactions involving the alter- 
nate pathway for complement activation, and 64% are 
caused by other pseudoallergic mechanisms, mostly 
type I .:lo 
Among the allergic reactions (Table I), types I and 
III are predominant in the adverse drug reactions 
observed in anesthesia.“” Type I allergic reactions re- 
sult from the crosslinking of cell-bound immuno- 
globulin (IgE) on mast cells or basophils by antigen. 
These cells then release a host of mediators including 
histamine, prostaglandins, leukotrienes, platelet ac- 
tivating factor, and chemotactic factors. Hence, the 
causal role of histamine must be analyzed in those 
reactions.:” Adverse responses caused by thiopental, 
neuromuscular blocking agents, or chymopapain can 
be via a type 1 allergic nlechanism.H In type III allergic 
reactions, the antigen-antibody complex causes com- 
plement activation that also leads to mast cell degran- 
ulation via several anaphylatoxins. In addition, 
polymorphs are attracted, platelet activation occurs 
Table 1. Classification of Allergic and Pseudoallergic Reactions by Pathomechanisms 
Allergic Pseudoallergic 
Type I: Anaphylactic 
Antigen reacts with cell-bound IgE (occasionally 
IgG subclasses). 
Type II: Antibody-dependent cytotoxic 
Antibodies bind to cell-bound antigens. 
Type III: Complex-mediated 
Circulating antigens and antibodies combine to 
form complexes. 
Compound stimulates mast cell or basophil secretion by acting 
directly at receptors, by releasing or forming mediators, or by 
modulating second-messenger systems. 
‘l’ype II: Cytotoxic pseudoallergic 
Compound causes cell damage or cytolysis by direct effects on 
membranes and/or other cell components, or by activating 
cytotoxic mediator systems (alternate pathway, coagulation 
and fibrinolysis, elastase, etc.). 
Type III: Complex-mediated pseudoallergic 
Compound binds to membranes and/or circulating cells 
(thrombocytes, etc.) to activate the alternate pathway of the 
complement system. 
Type IV: Cell-mediated (delayed) ‘Type IV: Cell-mediated (delayed) pseudoallergic 
Antigen reacts with endogenous receptors on Compound elicits the clinical picture by acting at receptors 01 
primed T lymphocytes. cell membranes of T lymphocytes or macrophages. 
- 
From Ennis and Lorenz~g with permission. 
Type I: Anaphylactoid 
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with mediator release, and the formation of micro- 
thrombi and macrophages are activated. Such reac- 
tions are observed, for instance, after dextran, contrast 
media, or protamine administration.8,1”J’ 
Among the pseudoallergic reactions (Table I), those 
of type I predominate in anesthesia and surgery. Di- 
rect release of histamine from mast cells or basophils 
has been demonstrated for many agents, including 
opioids, hypnotics, muscle relaxants, plasma substi- 
tutes, antibiotics, and radiographic contrast me- 
dia.“~“~” ‘I-he solvents or other agents in formulation 
for intravenous (IV) use can also directly release his- 
tamine. For instance, cremophor El@ is still used as a 
solubilizer in formulations of steroid hormones, cy- 
closporin A, glycerol trinitrate antibiotics, vitamins, 
among others, and was also included in the formu- 
lations of propanidid and althesin, which have heen 
removed from the market because of the unaccept- 
ably high incidence of reactioIis.‘.“,“,“” Cremophor 
lXt;,l”” camlot only directly release histamine from some 
mast cell types but may also modulate (potentiate or 
inhibit) the histamine release caused by other agents.:‘Z 
IIistamine can be directly administered to the patient 
during blood transfusions and in coronary bypass 
sur775gery.‘l.:‘: Histamine impurities in commercial 
heparin also can lead to the direct administration of 
‘+’ histamine to the patient.- I‘he histamine content of 
1.5 clinically used heparin samples from 5 companies 
varied 50-fold (Tddc 2). UsiIlg a dose of 400 IUikg 
applied as a bolus, about 340 ng histamine could be 
administered to the heart and cause the symptoms 
observed hy Adt et al.:” Disruption of mast cells (r.g., 
mechanically through surgical trauma) also causes his- 
tamine release.” Finally, histamine also cm be re- 
leased by activation of the alternate pathway of the 
complement cascade” via insoluble protein com- 
plexes, talcum powder, or tissue detritus as a type III 
pseudoallergic mechanism (Tublr I). 
Thus, there are many mechanisms that can elicit 
adverse histamine release reactions. Only by combi- 
nation of in -i&o studies, in zho animal trials with 
designs based on the clinical situation, volunteer trials, 
and prospective controlled clinical trials can the mech- 
anisms be elucidated.“’ An understanding of the un- 
derlying mechanisms can lead to product improvement 
and hence a reduction in the incidence and/or severity 
of reactions.2’,X!’ 
Diagnostic Predictors of Histamine 
Release Reactions 
Clinical judgment on incidence, severity, and clinical 
relevance of these reactions depends strongly on the 
Table 2. Histamine Content in Different Clinical 
Preparations, Batches, and Pharmaceutical Formulations 
of Heparin 
Heparin Preparation Histamine Content 
Number @w) 
6 
8 
9 
10 
II 
12 
IY 
14 
15 
Median 
(range) 
1.34 
6.22 
0.90 
3.60 
0.40 
9.62 
6.22 
0.24 
13.44 
5.00 
11.64 
0.44 
6.04 
0.72 
4.55 
4.55 
0.24- IS.44 
pg/lU = picogram/international unit. 
The heparin preparations were obtained from the following com- 
panies: Braun Melsungen, 3508 Melsungen (FRG); Hoffmann-La 
Roche, 7889 Grenzach-Wyhlen (FRG); Nordmark, 2082 Uetersen 
(Holstein) (FRG); Organon, 8042 Oberschleipheim (FRG); Ratio- 
pharm, 7902 Blaubeuren (FRG). 
All vahles are the means of 3 determinations. Histamine was meas- 
ured by the combined fluorometric technique.” I.* 
improved accuracy in diagnosing them in the clinical 
scenario of operative medicine.28 Methods of objective 
medical decision making (decision matrix, receiver- 
operating characteristic curve,*8 independence Bayes, 
and step-wise logistic regression35) were combined with 
randomized clinical trials,25,36 histamine injection,‘Z,2H 
and infusion’.“i.38 techniques in human volunteers, 
administration of exogenous histamine and histamine 
releasers to the same subject within 30 minutes,gR,3Y 
and plasma histamine assays in combination with pro- 
phylactic application of H ,- + H,-antagonists.‘“,37,38 
The result was a set of predictors for diagnosing his- 
tamine release reactions that differs considerably from 
the set of predictors found in standard medical teach- 
ing (Table 3). 
Restriction of the symptoms to skin responses, hy- 
potension, and bronchospasm usually leaves only the 
skin response, since cardiovascular and respiratory 
disturbances for various reasons are not uncommon 
in anesthesia and surgery. This restriction of symp- 
toms may lead to a severe underestimation of the 
incidence of reactions. Furthermore, since not all 
agents produce the same set of predictors, the symp- 
toms that can be used to define a reaction also vary 
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Table 3. I’rc~lic.~ors ((kjtttplaint~, (:littical Sigtj?, Hiolo~ic~;rl Reactions) lot- 
I~~s~d~lishetl in ;I Variety of’ (:littic~;tl ‘l‘rials 
Skin 
Gastrointestinal 
Tract Respiratory Tract 
Head and Nervous 
System 
Heart and 
Circulation 
-.._..-.-. ____ 
settsatiott 01‘ lleilt metallic Ltste sneeAng linnitus txliy 01‘ I~txtlvc~;JJxli~t 
I-ed ears salivatiott snuffling cutig~stiott itt thr tlistttrhetl 
rrytllrlll;l heartbur11 stlltf) 110sc I’twl ;ttriovettlt-ic &I- 
Illlsh epigastric fullness n;lsal c-;lMThra l~ulsatiott in the c~olltlllc (iOIl 
hives (wheals) na1tsea nxrowttcss in the t~tttljoral regiott h) 1’0- (‘I 
pmritrts wtriiting ~hl-lJ;tt tleatlx~he hyfwt~lm~ioti 
conjuncTivitis R;is1tmintestinal pain n;~rrowttess in the (It-owsittess (.il~(~tllillOl~\ ;ltJtl 
blephar-edemt (mitnps, colics) cl1rsr di/./ittcss c at-tli;ic 
s\volletl wrs straining coughitig wet w?s/le;lt~s ittsul’l ic ietic 1’ 
ctletn;l defecation respiratory distress ~igttat’iort c it~c.ul~ilor\ and 
l,r-oll~tlos~‘;l”tll sctJs;Jriott of It;~ngovet- c ;it.did( ,riwst 
All rhcsc I)reclic-tom werr cstablislml in pt-osprcti\c tl-ids 01 I.(I~x~IJ~ and Doenic kc.” I.OIX~II/ c( ;II.,~‘+ Oltma~tt~ c’t al..” Kalitwr u ,II.,~~ :’ l~t~d 
from drug to drug. In the case of atracurium, these 
symptoms were cutaneous signs and changes in heart 
rate (HR) (tachy- and bradycardia).“’ In the case of 
polygeline (Haemaccel), the symptoms were tachy- 
cardia only and hypertension, whereas flush and 
erythema were observed in only about 30% of indi- 
viduals.‘* In the case of heparin during cardiac sur- 
gery, only arrhythmias+’ were detected; and histamine 
release by the Hz-antagonist cimetidine and ranitidine 
was accompanied by metallic taste, headache, changes 
in HR and blood pressure (BP); ranitidine always 
caused a pale face, neck, and chest.:‘” The reasons for 
the different sets of diagnostic predictors are mast cell 
heterogeneity in their response to different drugs,” 
additional effects of these agents that act as functional 
or receptor antagonists, 42 the site and type of appli- 
cation of these agents, and other mediators that are 
released or formed by the released histamine (p.~., 
bradycardia induced by noradrenaline release).‘:’ 
In addition to histamine release, these drugs can 
also cause adverse reactions by other mechanisms (r.g., 
myocardial depression, ganglionic blockade) and, 
hence, complicate the accurate diagnosis of the re- 
actions not only by the omission of, but also by the 
addition of symptoms/signs.40~‘2 Therefore, only one 
test is available at present for the 95%’ accurate di- 
agnosis of a histamine release reaction: increased 
plasma histamine levels.21~zx~40 
Histamine release reactions can be divided into three 
grades of severity.‘” Grade I reactions are local (cu- 
taneous) reactions. The clinical symptoms include er- 
ythema, urticaria and/or dermal pruritus only. These 
reactions are not considered as threatening as the other 
two grades and no intensified observation or treat- 
ment is necessary. The plasma histamine concentra- 
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tions are less than or equal to 1 ngiml. (irade II 
reactions are systemic. ‘I’hey include generalized skin 
reactions plus discomfort, tachy- or bradycardia, other 
types of arrhythmias, medium hypo- or hypertension, 
and respiratory distress. These reactions are consid- 
ered threatening by both the patient and the doctor, 
and close observation and/or treatment is necessary. 
Plasma histamine levels are > 1 ng/ml. ‘I’he life-threat- 
ening reactions are grade III. Symptoms observed 
include severe hypotension, ventricular fibrillations, 
cardiac arrest, bronchospasm, or respiratory arrest. 
‘These reactions are considered life-threatening by the 
doctor and require emergency treatment. The plasma 
histamine levels in these patients are > I2 ng/nL2x 
Situations during the Perioperative Period 
Leading to Increased Plasma Histamine 
Levels and Histamine Release Reactions 
Increased plasma histamine concentrations and ad- 
verse reactions for which histamine is a necessary, 
sufficient, or contributing determinant,‘<’ occur 
throughout the perioperative period.“.i?,“.L4 ‘l‘hese 
increased histamine levels have been demonstrated in 
disease states of patients before they enter the oper- 
ating room (OR), e.g., in polytrauma,” septic shock,“‘,” 
upper gastrointestinal (GI) bleeding,l’ intestinal is- 
chemia, i4,tX renal failure,” and mastocytosis.2’ The ad- 
verse reactions have been shown in these clinical 
situations by several methods, since the conditions were 
very complex for a single mediator in these disease 
states: multivariate causality analysis in septic shock,‘+” 
assessment of stress ulceration in polytrauma,2’ effect 
of H,- + HZ-antagonists on the survival time in in- 
testinal ischemia.48 
The measures that occur before surgery and are 
associated with increased plasma histamine levels in- 
clude endoscopy’!’ and catheter insertion.” Lindlar et 
aL4” examined four groups of patients scheduled for 
follow-up endoscopy (esophageal varices, duodenal 
ulcer, duodenal ulcer after selective proximal vagot- 
omy, and nonspecific abdominal pain). The frequency 
of increased plasma histamine levels was between 19% 
and 28%, the highest occurrence rate being observed 
in the group with esophageal varices. The highest 
plasma histamine concentration was 6 ng/ml. If emer- 
gency patients with upper GI bleeding then have a 
histamine release reaction either due to the endoscopy 
itself” or to any drugs that may be preoperatively 
given, their reactions may be more severe than in 
those patients undergoing elective surgery. In an an- 
imal model for this hypothesis, it was shown in dogs 
following blood loss and isovolemic hemodilution’” 
that the same histamine release was much less toler- 
ated than in normal, unpretreated animals, and was 
associated with considerable mortality. 
The most dangerous period for histamine release 
reactions, however, is at anesthesia induction (Table 
4). l.‘L1,2R.R1.34.~9,5061 All of the drugs used can cauSe 
increased plasma histamine levels and also unwanted 
histamine release reactions including, at the min- 
imum, increased gastric secretion’” and cardiac 
dysrhythmias”’ as the most sensitive responses to his- 
tamine. In addition, all other drugs administered for 
the prevention of surgical complications, such as hep- 
arin,:<” protamine, WM and antibiotics such as vanco- 
m ycin,““ metronidazole, and cephalosporines,‘;” can 
also cause histamine release and adverse reactions. 
The vast range of‘ agents causing histamine release 
and reactions and the relatively high incidence of such 
events (Table 4) should serve as a warning, since all 
of these drugs are used routinely. In severely ill pa- 
tients, even a minor (< 1 ngiml) or medium (l- 10 
ng/ml) plasma histamine level otherwise well tolerated 
by a healthy person, in combination with other mech- 
anisms or mediators such as in polytrauma,Z’,f” septic 
shock,‘“,*” or following bone cement implantation in 
an elderly patient ,‘,i can lead to death, as multivariate 
causality analysis has shown.‘*4,“7 
Furthermore, the modulation of histamine release 
through administration of a mixture of drugs at anes- 
thesia inductionzfi must be considered. Thus, drugs 
which alone release little or no histamine may cause 
medium or severe reactions in combination with other 
agents.% Although etomidate rarely releases hista- 
mine when given alone, the authors found that when 
it was given after muscle relaxants, the timing of the 
adverse reactions suggested that etomidate might it- 
self have caused some histamine release.“8 Similar 
findings were observed after lormetazepam admin- 
istration was followed by etomidate.“” In a random- 
ized trial, 24 patients received either nalbuphine or 
fentanyl as analgesics during routine anesthesia.M Five 
of 11 patients had increased plasma histamine levels 
after fentanyl, and 6 of 13 patients after nalbuphine. 
However, after induction of anesthesia with alcuron- 
ium, flunitrazepam, and thiopental, only 1 patient 
had increased plasma histamine levels in the fentanyl 
group, but 6 patients had increased plasma histamine 
levels in the nalbuphine group (p < 0.05). 
Surgical procedures themselves, in phases in- 
dependent of anesthesiological measures, release 
histamine,?1.& 1,SO,(ii.(iX In five standard operations (thy- 
roidectomy, lobectomy or pneumectomy, cholecystec- 
tomy, anterior colorectal resection, and aorto-femoral 
bypass operation), increased plasma histamine con- 
centrations were found during one or more defined 
phases such as body cavity exploration and detach- 
ment of adhesions.fix Other surgical interventions pro- 
ducing increased plasma histamine levels include 
resection of liver segments and the esophagus,“” kid- 
ney and liver transplantation,” aneurysmal clipping,‘” 
pediatric cardiopulmonary bypass.” and bone cement 
illiplantatioll.“‘.i’ 
A special situation during surgery in which free 
histamine is infused via a central catheter directly into 
the heart and the pulmonal circulation is the admin- 
istration of erythrocyte concentrates for blood trans- 
fusion. Histainine concentrations are high in the 
“plasma supernatant” of these infusion mixtures, es- 
pecially toward the end of administration when high 
pressure is applied to push the residual blood through 
the stuffed filters (Figure l).f’x 
Pharmacology of Histamine Receptor 
Antagonists: Pharmacokinetics and 
Adverse Reactions 
Histamine Receptors 
Histamine exerts its physiological actions by binding 
to specific receptors. ‘~3 Three receptor types for his- 
tamine have been found: H,, HLL, and H,. These re- 
ceptors are defined pharmacologically by the actions 
of their agonists and antagonists. Histamine via the 
H, receptors mediates the following biological effects 
in humans: decrease in atrioventricular node con- 
ductance, coronary artery constriction, vasoconstric- 
tion (blood vessels > 80 km), vasodilation (blood vessels 
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Table 4. Drugs that (&se Increased Plasma Histamine Levels and Advel-se 
l&actions as Demonstrated in Clinical Trials with Volunteers or Patients 
Drug Incidence* 
Author and 
Reference Number 
Hypnotics 
Thiopental sodium 
Methohexital 
Propanidid 
Althesin 
Opioidc 
Morphine (IV) 
(oral) 
Fentanyl 
Alfentanil 
Nalbuphine 
Muscle Relaxants 
Atracurium 
Alcuronium 
Pancuronium 
Succinylcholine 
d-Tubocurarine 
Benzodiazepines 
Lorazepam 
Diazepam 
Plasma Substitutes 
Polygeline classical 
(old formulation 
Haemaccel) 
Dextran 
Oxypolygelatin 
Hydroxyethyl starch 
Antihistamines 
Dimetindene 
Promethazine 
Cimetidine 
Ranitidine 
Other Agents 
Atropine 
Saline 
Methylprednisolone 
Heparin 
9110 (90%) Lorenz et al.’ 
618 (75%) Lorenz et al.i” 
lO/lO (100%) Lorenz et al.’ 
218 (25%) Doenicke et al.2 
16132 (50%) Lorenz et al.” 
418 (50%) Doenicke et a1.2 
2111 (18%) Watkins et al.” 
25125 
6115 
6116 
0125 
4120 
218 
l/l0 
6116 
(100%) 
(40%) 
(38%) 
(0%) 
(20%) 
Philbin et aLs? 
Suttmann et al.“” 
Suttmann et al.s” 
Philbin et al? 
Lorenz et al.‘.’ 
Doenicke et al.“” 
Doenicke et al.“% 
Suttmann et al.” 
819 (89%) Scott et aL5” 
16141 (39%) Barnes et al? 
218 (25%) Lorenz et aLss 
l/7 (14%) Lorenz et aLix 
318 (38%) Lorenz et al.‘# 
14/20 (70%) Moss et al.” 
3110 (30%) Doenicke et al.b” 
Oil0 (0%) Doenicke et aLh0 
32150 
2110 
301168 
12140 
9128 
l/IO 
2/10 
(64%) 
(32%) 
(10%) 
(20%) 
Lorenz et al.“’ 
Lorenz et aLsn 
Lorenz et al.‘* 
Lorenz et aLYH 
Lorenz et al.“’ 
Lorenz et al.jx 
Lorenz et al.ih 
o/7 (0%) Lorenz et al.” 
o/10 (0%) Lorenz et aL2’ 
6115 (40%) L orenz 1 et al.‘!’ 
4114 (27%) Lorenz et al? 
6136 (17%) Lorenz et al.“” 
4122 (18%) Lorenz et al.“’ 
317 (43%) Lorenz et al.tvl 
818 (100%) Adt et al.‘” 
*Incidence of increased plasma histamine levels. 
IV = intravenous. 
< 80 km), increased vascular permeability, pruritus, The actions via H, receptors include increase in 
bronchial constriction, activation of airway vagal af- HR and myocardial contractility, coronary vasodila- 
ferent nerves, smooth muscle contraction in the GI tion, peripheral vasodilation (blood vessels < 80 pm), 
tract, and release of catecholamines from the adrenal bronchial dilation, increase in airway mucus secretion, 
medulla.‘3,7”r75 esophageal contraction, and gastric acid secretion. The 
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Figure 1. Histamine concentrations in the “plasma super- 
natant” of erythrocyte concentrates used for blood trans- 
fusion in the study of Riiher et aLbH Units of concentrates 
were obtained from a local blood bank, dissolved in saline 
or fresh frozen plasma immediately before use, and passed 
through at IO km microfilter. NaCI = sodium chloride. 
combined action of histamine on H, and H, receptors 
in an additive way mediates hypotension and decrease 
in systemic vascular resistance (SVR), flushing, and 
headache. In addition, histamine H, and H, receptors 
are found in many blood cells: T-cells (suppressor T 
cells, helper T cells, cytotoxic T cells (HJ), B cells (H,), 
neutrophils, basophils, eosinophils, and monocytes. In 
the brain, both H, and H, receptors have been found; 
indeed, mammalian brain has the highest density of H, 
binding sites of any organ studied.13.74m56 
Recently, the H, receptor, which is involved in the 
feedback control of histamine release from presyn- 
aptic sites, has been described.” Its presence also has 
been described in rat brain and lung. However, a 
Periope7-atiue uses of histamine antagonists: Lorenz et al. 
function for these receptors has not yet been shown 
to be involved in anesthesia and surgery. Hence, the 
remainder of the article focuses only on H, and H, 
receptor antagonists. 
Histamine H, Receptor Antagonists 
An exceedingly large number of H, receptor antag- 
onists are available; however, only a few have been 
used in anesthesia and surgery. This situation is mainly 
due to their lipophilic properties; since they are in- 
soluble in water, they are not available for IV admin- 
istration. The authors, therefore, concentrate on those 
agents most commonly used in different countries: 
chlorpheniramine, dimetindene, hydroxyzine, cle- 
mastine, and promethazine. Most of these prepara- 
tions have been available for 20-30 years and few 
formal pharmacokinetic studies have been per- 
formed, especially after IV administration (Table 
5). 13.i8.7’J However, data on blood levels are insufficient 
to provide information on the rapidity of onset of the 
protection, effectiveness of this protection against life- 
threatening reactions, and duration of this protection. 
The binding to the histamine receptors and, after 
signal-transducing, the final biological reaction, are 
obviously the most important features. These data are 
available only from two published studies in dogs21,80 
(Tuble 6). Against life-threatening reactions with plasma 
histamine levels comparable to those in human sub- 
jects, 1~6~‘L’.55 the H,-receptor antagonist is less effective 
(about one-half as effective) than the combined H,- 
+ H,-prophylaxis. The prophylaxis is protective if 
administered 15 minutes before the substance pro- 
ducing the adverse reaction and also protective after 
2 hours. Methylprednisolone, even administered 2 
hours before the histamine releaser, was ineffective 
in the low dose and worse than placebo in the high 
dose. 
Table 5. Pharmacokinetic Data for Histamine H,- + H,-Receptor Antagonists 
Pharmacokinetic Parameter 
H,-Receptor Antagonists Hz-Receptor Antagonists 
Hydroxyzine Dimetindene Cimetidine Ranitidine 
Bioavailability (f, R) - 74 62 52 
Volume of distribution (V,,, 1) 16 1x4 70 126 
Total body clearance (Cl, 1) 41-69 26 32 42 
Elimination half-life (t l/2, h) 14-20 5 2 2 
Data compiled from refs. 78,79 for hydroxyzine, from Arnera V (Zyma,Nyon (Switzerland)) for dimetindene, and from ref. 13 for cimetidine 
and ranitidine. Volume of distribution and total body clearance calculated for a human subject of 70 kg. Bioavailability after oral 
administration. 
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Table 6. Life-Threatening Histamine Kelease Reactions in Dogs in a Model 
fix- Pseudoallergic Reactions to Plasma Substitutes: Influence of H,- + tI,- 
receptor Antagonists and Low-Dose and High-Dose Methylprednisolone on 
Hypotension and Histamine Release 
Prophylaxis 
Hypotension Increase in Plasma Histamine 
(mmHg, k (range)) (nglml, X (range)) 
NaCl 
H 
H, + H, 
MP3 
MP15 
N&l 
H, 
H, + H, 
MP3 
MPIS 
(a) Drugs administered 15 min before plasma substitution 
60 (O- 120) ; ] :; (52.5-227) 
“8 (O-X5) (O- 120) 
0 (040) 10.5 (O.!)- 104) 
63 (O- 120) 32.2 (0.G 17X) 
xx (O- 140) 90 (0.G-M7) 
(b) Drugs administered 2 h before plasma substitution 
50 (O-1 IS) 3?.H (O- 1!)2) 
3.S (O-!)O) ‘L’L.4 (2% 1 16) 
0 (O-60) I:$.!) (1.2-105) 
43 (O-93) 23.6 (O-IX”) 
.5,:5 (1 O-95) 40.X ( 1 .H- 132) 
Maximum hypotension (syslolic blood pressure 5-X min after starting infusion) 2nd histamim 
release at this rime following bleeding of one-third of blood volume and I min Iarct- plasma 
substitution by Ringer containing 50 k&g 4X/X0 as a typical histanlilw I-eleasc~. As it1 hutwn 
studies,‘” not all animals react to the histamine releaser. but only 2 pro\cn porficul (large 
range!). NaCI = sodium chloride; El, = 0.5 mgikg dimentidcne; tl, = 5 nrgikg c imclitfinr: 
MW = 3 mgikg methylprednisolo~~~: MI’15 = I5 mg/kg nrethylpt-ctlnisc,lotlc. K;mdomixtl 
double-blind trial, 12 animals/group. I~asal plasma histamine Ic\d 0.3 11g/n11 as ill IIII~;~II\. 
From Diet7 el al.,“” with pernlission. 
All H,-receptor antagonists have many effects in 
addition to their “specific” antihistaminic prop- 
erty. 13.X1,R2 Some of these effects are beneficial in pseu- 
doallergic and allergic reactions if they attenuate the 
effects of other mediators such as serotonin and bra- 
dykinin.81 However, most of these drugs act on the 
central nervous system (CNS), with both stimulation 
and depression being observed.13J* For example, 
chlorpheniramine produces stimulation and clemas- 
tine fumarate often causes drowsiness. Dimetindene 
elicits only little sedation, as shown by several psy- 
chometric tests and electroencephalographic (EEG) 
analysis.2’ Hydroxyzine is a long-acting compound 
(Table 5) with considerable central depressant activity. 
However, when given with morphine for postopera- 
tive pain, hydroxyzine provides better pain relief than 
does morphine alone.83 Promethazine hydrochloride 
is the most sedating agent of its groupig and is still 
often used for its antiemetic affects. It potentiates the 
action of the narcotics morphine, pethidine, fentanyl, 
and pentazocine. 84 Some of these H,-receptor antag- 
onist side-effects on the CNS may be judged dif- 
ferently in anesthesiology than in other medical dis- 
ciplines. Sedation or potentiation of the effects of other 
drugs may be welcomed. However, these effects should 
always be considered. 
Histamine H, Receptor Antagonists 
Until now, two commercially available H, receptor 
antagonists, cimetidine and ranitidine, have been used 
in the perioperative period. A wealth of pharmacoki- 
netic data is available (Table 5), but, again, the binding 
of the compounds to histamine receptors is a more 
important feature (Table 6) than is the pharmacoki- 
netic data based on plasma levels. 
H,-receptor antagonists have side effects in addi- 
tion to their desired actions. However, adverse reac- 
tions to these agents are extremely rare and have been 
observed only after repeated and chronic use, ~.g., 
agranulocytosis or hypothalamic-pituitary-gonadal 
dysfunction.x” There are, however, findings that must 
be considered by the anesthesiologist: 
1. Hemodynamic effects: Rapid IV administration of 
HZ-receptor antagonists should be avoided. It leads 
to histamine release and, hence, bradycardia, hypo- 
tension, and other cardiotoxic effects.3Y This reaction 
is not seen after slow infusion.6i 
2. Drug interaction: Both cimetidine and ranitidine 
bind to cytochrome P450 but the binding is weaker 
for ranitidine. This fact can lead to accumulation of 
drugs that undergo oxidative degradation, e.g., war- 
farin, diazepam, theophylline, phenytoin, carbama- 
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zepine, lidocaine, propranolol.R6 However, there are 
always other drugs from the pharmacological class 
that can be substituted, thus eliminating the problem 
(e.g., substituting oxazepam or lorazepam for diaze- 
pam, using nadolol or atenolol instead of proprano- 
lol.)H’ 
3. Neuromuscular rffects: The anticholinesterase andi 
or ganglionic blocking activity of the HZ-receptor an- 
tagonists might influence the cardiovascular status of 
the anesthetized patient. x7 However, their pharma- 
cological effects at cholinergic sites have been ob- 
served only at high drug doses. Cimetidine has no 
effect on succinylcholine-induced neuromuscular 
blockade.xx Cimetidine (not ranitidine) prolongs the 
effect of vecuronium. The action of the H,-receptor 
antagonists on bupivacaine pharmacokinetics has 
been described as without effecP or with a reduced 
bupivacaine clearance after cimetidine.“” H,-receptor 
antagonists have no effect on lidocaine concentrations 
during epidurals.“’ 
4. C[L.ctroiniustintLl effects: The administration of H,- 
receptor antagonists in combination with H, antihis- 
tamines brings the added bonus of increasing gastric 
pH and reducing gastric volume.!‘2 Thus, they can 
prevent the risk of acid aspiration or aspiration pneu- 
monitis in groups at risk (e.g., grossly obese patients, 
obstetric patients, children, or patients undergoing 
major abdominal surgery).“” 
5. Mend confusion: This effect of H,-receptor an- 
tagonists has been observed in chronically ill patients 
with renal and hepatic failure, especially after the full 
dose for prevention of stress ulceration in intensive 
care units (ICU).r’n,‘rs This effect, however, can be ex- 
pected only after treatment for several days and, hence, 
does not play a role in a single dose of antihistamines 
before operations.“2 
Effectiveness of a Combined Prophylaxis 
with H,- + Hz-receptor Antagonists to 
Prevent Histamine Release Reactions 
(Pseudoallergic/Allergic Reactions) during 
the Perioperative Period 
A series of randomized clinical trials have demon- 
strated clearly that histamine release reactions of all 
degrees and severity are associated with the various 
phases of the induction of anesthesia, intraoperative 
measures, or drug delivery. In these trials, the effec- 
tiveness of a combined H,- + H,-premeditation was 
proven (Table 7): y4 loo The fn-st of these trials was per- 
formed as long ago as 1977.n5 Since then, this pre- 
medication has been shown to be totally effective 
against anaphylactoid adverse drug reactions of at 
least grade 2 severity (systemic reactions). However, 
there has been a reluctance to use this strategy despite 
its documented effectiveness in clinical trials.‘” The 
reason for this reluctance is not completely clear in 
the same way as is the reluctance to accept the high 
incidence of histamine release and histamine release 
reactions (see Introduction). 
The first argument frequently raised against the 
use of antihistamine prophylaxis is that many media- 
tors other than histamine are released from mast cells 
and basophils. Thus, antihistamine prophylaxis would 
be expected to be effective only against reactions me- 
diated by histamine. This line of reasoning is not sus- 
tained by clinical experience in which it is documented 
that the incidence and severity of reactions are greatly 
reduced even in situations where histamine is not the 
predominant causal factor.“1.“7.10” However, in vitro 
studies have shown that antihistamines in low con- 
centrations are able to inhibit histamine release from 
mast cells and to protect rat erythrocytes against os- 
motic shock, probably by stabilizing the cell mem- 
branes. “)’ The combination of H,- + H,-receptor 
antagonists led to a synergistic enhancement of the 
inhibition. These findings have been supported by 
animal studies in uizw. 21~xo In Tublr 6, the reduction in 
histamine release is up to 80%. In a controlled clinical 
trial investigating reactions to atracurium, similar 
findings were first reported for the clinical situation.,“’ 
In the placebo group, 65% of patients responded to 
atracurium with a measurable clinical syndrome, a 
histamine release reaction. ‘I‘hese reactions were re- 
duced to 15% by the use of H,- + HZ-receptor an- 
tagonists. More histamine release without clinical 
symptoms was observed in the H,- + HZ-group, but 
the extent of the histamine release was markedly re- 
duced. Since histamine release is involved in the proc- 
ess of liberating or forming other mediators,lCP1 
inhibition of histamine release also prevents the re- 
lease of other mast cell-derived mediators. All of these 
findings provide a rationale for the use of H,- + H,- 
receptor antagonists, even in situations where hista- 
mine is not the predominant mediator involved in the 
reaction (such as in gelatine plasma substitutes and 
morphine)“’ but also in nonanaphylactic reactions, or 
even after complement activation by radiographic 
contrast media :+(1.97-W 
The second argument frequently proposed is that 
this premeditation is not strong enough for life- 
threatening reactions. This speculation was clearly 
shown to be False with data from a number of animal 
experiments (Tuble 6).“,80 It was, however, also shown 
to be false in a large prospective study on chemo- 
nucleolysis by chymopapain in 3 1,585 patients (Table 
7). 100 
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Table 7. (Xnical Trials Investigating the Ef’fectivenrss 01 ;I (:ombinetl Prophylaxis with H ,- antI H,-receptors :\11tag:o111~1\ 
to Prevent Adverse Pseudoallergic/AIlergic- Reactions 
Drug, Severity of Reactions, Number of 
Patients, Antihistamines Used Result 
Author and 
Reference Number 
Induction of anesthesia and preparation of the surgical patient 
Morphine (I mgikg), grade 2 Cardiac- index (CI) unchanged, diastolic, 
40 patients, cardiac bypass surgery blood pressure (DP) slightly reduced (7 tort‘) 
diphenhydramine 1 mg/kg H, + H,. 
cimetidine 4 mg/kg Cl increased, DP reduced by ca. 26 tori 
saline, p < 0.05 
Propanidid, grade I + 2 
32 volunteers 
dimetindene 0.1 mg/kg + 
cimetidine 10 mg/kg 
4116 with flush H, + H.. 
1 l/l6 flush saline 
tachycardia significantly reduced in 
H, + H, group 
p < 0.02 
Suxamethonium, grade 1 + 2 
SO surgical patients 
(20 saline, 20 H,, 20 H, + H,) general 
surgery 
1120 had increased HR > 9 beatsimin (H, + 
H,) W20 (saline), 6/20 (H,) p < 0.01 H, + H, 
v. saline 
promethazine 0.5 mgikg (i.m.) + cimetidine 
400 mg (i.m.) 
d-Tubocurarine, grade 2 + 3 
24 patients (placebo, H,, H,, H, 
cardiac surgery 
chlorpheniramine 0.1 mgikg 
cimetidine 4 mgikg 
Atracurium, grade 1 + 2 
40 patients, general surgery 
dimetindene 0.1 mgikg 
ranitidine 1.25 mg/kg 
Polygeline, grade 1 + 2 
50 volunteers 
dimetindene 0.1 mg/kg + 
cimetidine 5 mgikg 
Polygeline, grade I 
- HA, 
H, + H, reduced decrease in SVR caused by 
tubocurarine 
p < 0.05 
0120 histamine release reactions H, + H, 
1 O/20 reactions saline 
p < 0.01 
0125 reactions H, + HZ 
9/25 reactions saline 
p < 0.01 
41150 reactions H, + H, 
300 patients, orthopedic surgery 
dimetindene 0.1 mg/kg or chlorpheniramine 
0.3 mgikg + cimetidine 5 mglkg 
271 I50 reactions saline 
p < 0.005 
DSA, Ultravist, grade 1-3 
200 patients, radiodiagnostics 
dimetindene 0.1 mg/kg + cimetidine 
5 mg/kg 
Urography, Telebrix, grade 1 + 2 
500 patients, urology 
dimetindene 0.1 mgikg + cimetidine 
5 mgikg 
Intraoperative measures and drug delivery 
l/l00 mild reaction H, + H, 
51100 reactions saline 
p < 0.05 
Urography, amidotrizoate, grade 1 + 2 1% incidence with H, + H, 
196 patients H, + H,, 194 patients saline, 4.6% incidence saline 
urology p < 0.05 
clemastine 0.03 mgikg + cimetidine 5 mg/kg 
Palaces implantation, grade l-3 
20 patients, emergency surgery 
clemastine 4 mg + cimetidine 400 mg 
Changes in systolic blood pressure (SP) and 
DP and number of therapeutic interventions 
reduced with H, + H, 
p < 0.01 (BP), p < 0.05 (interventions) 
161300 reactions H, + H, 
76/200 reactions saline 
less severe reactions with H, + H, 
Philbin et aI?’ 
I‘ryba rt al.“’ 
Inada et al.” 
Doenicke et al. “I 
Schiining et al.“l, 
Schiining et al.‘“, 
Beyer et al.“’ 
‘Tauber et al.“” 
Ring et al.“” 
Tryba et al.?? 
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Table 7. Continued 
Drug, Severity of Reactions, Number of 
Patients, Antihistamines Used 
Chymopapain, chemonucleolysis, 
grade 3, 2 study periods: 
I n = 1585 patients without H, + H, 
II n = 30,000 patients with H, + H, 
Result 
15.4% anaphylactic reactions resulted in 
death (I) 
1.6% anaphylactic reactions resulted in 
death (II) 
p < 0.05 
Author and 
Reference Number 
Moss et aP 
Trials listed in the sequence of their common use in anesthesia and surgery. All trials except the last were randomized controlled trials. 
DSA = digital subtracrion angiography; SVR = systemic vascular resistance; UltravisP = iopromide; Telebrix@ = ioxithalamate. 
Rationale for a Combined Prophylaxis 
with H,- and Hz-receptor Antagonists in 
Anesthesia and Surgery 
In all epidemiological and prospective studies re- 
ported (for individual data see refs. 5,9,10,21,28, 
40,103,104), life-threatening adverse reactions (grade 
3) in which histamine release is causally involved”’ 
occur in 0.1%0.5% of all patients undergoing gen- 
eral anesthesia and surgery. This incidence comprises 
approximately 15,000 patients per year in West Ger- 
many,5s but similar data have been reported for the 
United Kingdom. L03.104 Data from the Sheffield-based 
National Adverse Anesthetic Reactions Advisory 
Service (NAARAS) in the U.K. suggest “something 
between 5,000 and 10,000 clinically severe reactions 
each year in every European country.“‘O” These in- 
cidences of adverse reactions are in the same order 
of magnitude as perioperative thromboembolism, 
clinically severe bleeding from stress ulceration, and 
sepsis, all of which have led to prophylactic measures 
in a substantial proportion of surgical patients.40J0” 
However, cardiovascular instability observed in me- 
dium (systemic grade 2) reactions, which occur with 
an incidence of between 1-5%,21.28 are also undesir- 
able and should be thoroughly considered.21 More 
often than supposed, anesthetists treat with fluids, 
vasopressors, atropine, and other measures in cardio- 
vascular reactions which, after plasma histamine anal- 
ysis, are shown to be histamine release reactions.40 
Even minor increases in plasma histamine levels, in 
combination with other mediators, can increase mor- 
bidity and mortality, as shown for po1ytrauma,45.47 sep- 
tic shock,44 after administration of radio contrast 
media,gl or after administration of chymopapain.37 
Thus, both histamine release and the adverse reac- 
tions should be prevented. What approaches can be 
taken? 
The first step could be discarding all drugs known 
to release histamine. Some drugs have been removed 
from the market (propanidid, Althesinm). However, 
the number of drugs involved is so large that this 
option is not a viable solution. 
The second step could be product improvement so 
that less histamine release occurs. This option was 
chosen for the plasma substitute polygeline.j5 The 
original product was produced with a great excess of 
hexamethylene diisocyanate and caused severe reac- 
tions. The new formulation of purified polygeline 
(Haemaccel-35@) is produced with only a slight excess 
of hexamethylene diisocyanate over the stochiometric 
ratios and causes fewer, less severe reactions. 
The third step is to discard histamine-releasing sol- 
vents. The reactions are not always caused by the drug 
itself, often solvents such as Cremophor El@ are to 
blame. For example, propofol (Diprivan@) is now for- 
mulated with the IV fat emulsion Intralipid@ instead 
of‘ Cremophor El@, and the incidence of severe re- 
actions is decreased. Again, however, this option is 
not viable in all cases. 
The fourth step is more careful drug administra- 
tion. Rapid bolus injections produce significantly more 
histamine release than do shorter administrations. This 
finding has been demonstrated for thiopental, pro- 
panidid,93 and the Hz-receptor antagonist cimeti- 
dine.“’ Rapid injections should be avoided as much as 
possible. The practice of administering drugs via the 
same cannula without flushing can produce precipi- 
tates, causing, for example, complement activation via 
the alternate pathway.lQ3 
The above mentioned four measures to prevent 
reactions involve only single drugs. However, in anes- 
thesia many drugs are used concurrently (e.g., anal- 
gesics, hypnotics, muscle relaxants). Many different 
single agents from each group are available. The use 
of different combinations of drugs can result in more 
reactions than can the use of only one single agent. 
The combinations can cause a potentiation of the his- 
tamine-release response or a histamine-release re- 
sponse when the single agents themselves cause no 
reaction. Thus, the four measures are in most cases 
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not only unviable but also cannot guarantee preven- 
tion of the reactions. The final step, which the authors 
have consistently recommended for the last 15 years, 
is a prophylaxis with histamine H,- + H,-receptor 
antagonists. Histamine release reactions have not de- 
creased in the previous 10 years, as the authors long 
ago predicted.“” This fact is attributed to the use of 
new drug combinations (e.~., lormetazepam-etom- 
date, nalbuphine, and other induction agents, as shown 
in this article) or the use of new drugs such as atra- 
curium and also vecuronium, which have a high or, 
in the case of vecuronium, substantial incidence of 
histamine release.‘03~104 In addition, histamine release 
occurs after physical stress (e.g., intubation, endos- 
copy), during operations, by blood transfusion, etc. 
The authors have observed three to four separate 
occasions of histamine release during the preparation 
of single patients: ‘0~1J5 during peripheral access, after 
alcuroniurn, fentanyl, suxamethonium in combina- 
tion with intubation and volatile anesthetics, plasma 
substitutes, and, especially frequently, after the 
antibiotic”’ given just before skin incision. Finally, fol- 
lowing H,- + H,-prophylaxis, drugs which, except 
for their histamine releasing effects were well toler- 
ated, can be used again instead of drugs whose side 
effects may be more difficult to cope with. 
Clussijkation of Patients for Whom H ,- t 
H,-prophylaxis Should Be Recommended 
If practitioners do not want to give every surgical 
patient this prophylaxis, how can patients who are at 
risk for a more frequent or more severe reaction than 
Figure 2. Decision tree for heuristic decision making developed by the “think- 
aloud technique” with three experts. It includes nine hierarchically ordered 
decision nodes at which questions had to be answered. Data from different types 
of clinical studies such as controlled trials, epidemiological surveys, postmar- 
keting surveillance studies, and cost-effectiveness analysis were used in creating 
this tree. The final decision was acceptance of the prophylaxis.‘05 
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are normal patients be defined? The authors cite a 
number of indications which have been determined 
by heuristic decision making*l and by using a decision 
tree (Figure 2). lo5 Prophylaxis with H,- + H,-receptor 
antagonists should be used or at least considered: 
(1) in patients with a history of adverse drug reactions 
or history of allergy; (2) in patients who undergo sur- 
gery with a high risk of histamine release (transplan- 
tation, extracorporeal circulation, bone cement 
implantation); and (3) in patients >70 years and those 
with poor physical status (> ASA 3). 
Histamine is highly arrhythmogenic. It supports 
existing arrhythmias and potentiates an increased 
pulmonary shunt volume, especially in liver cirrho- 
sis.” Histamine is more effective in hypovolemic 
patients. 44 It was the probable cause of death in an 
80-year-old woman undergoing bone cement implan- 
tation.“” Histamine potentiates coagulation. Hence, it 
is conceivable that elderly patients and those with poor 
physical states suffer from more severe reactions to 
histamine than do healthy and fit subjects undergoing 
elective surgery. 
Mode of Administration qf H,- + 
H,-prophylaxis Recommended at Present 
When H,- + Hz-prophylaxis is administered, the fol- 
lowing conditions for drug administration are used: 
a slow infusion (about 3-4 minutes) of the H,- + H,- 
receptor antagonist dimetindene in a dose of 0.1 mgi 
kg and the H,-receptor antagonist cimetidine in a dose 
of 5 mgikg at least 10 minutes before the induction 
of anesthesia. This protection lasts for more than 2 
hours.‘1,X0 Less experience is available with raniti- 
dine,4O but a dose of 1.25 mg/kg IV was also found to 
be effective. 
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